ライフサイエンスコーパス: mixed lineage

1 roliferation in Lin(-) cells and led to more mixed lineage colonies from transduced KI BM cells.

2 mixed population, as a minority give rise to mixed-lineage colonies while the majority of cells are t

3 tor-interacting protein kinase 3 (RIPK3) and mixed lineage domain-like protein (MLKL), targeting necr

4 Here we show that the mixed-lineage dual leucine zipper kinase (DLK) is an ess

5 MLK4 is a member of the mixed-lineage family of kinases that regulate the JNK, p

6 ferentiated prematurely, and often adopted a mixed lineage fate.

7 e show that this analysis captured prevalent mixed-lineage intermediates that manifested concurrent e

8 This analysis identified mixed lineage kinase 3 (MLK3) as a putative NS5A interac

9 Mixed lineage kinase 3 (MLK3) deficiency reduces macroph

10 Mixed lineage kinase 3 (MLK3) functions in migration and

11 on in the kinase activity of a pro-apoptotic mixed lineage kinase 3 (MLK3) in HER2-positive (HER2+) b

12 Inhibition of mixed lineage kinase 3 (MLK3) is a potential strategy fo

13 noted that the activity of the proapoptotic mixed lineage kinase 3 (MLK3) kinase was relatively high

14 Mixed lineage kinase 3 (MLK3), a MAP3K member has been e

15 possible cross-talk between beta-catenin and mixed lineage kinase 3 (MLK3), a MAPK kinase kinase memb

16 protein (merlin/schwannomin) associates with mixed lineage kinase 3 (MLK3), a mitogen-activated prote

17 Mixed lineage kinase 3 (MLK3), also known as MAP3K11, wa

18 Here, we report that mixed lineage kinase 4 (MLK4) is overexpressed in MES bu

19 e mutational analyses have revealed that the mixed lineage kinase 4 (MLK4) protein kinase is frequent

20 ce did not occur via apoptosis, but required Mixed Lineage Kinase Domain Like (MLKL) and activation o

21 ptor-interacting protein kinase 3 (RIPK3) or mixed lineage kinase domain like (MLKL), two core protei

22 acting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL) and generally ma

23 Characterization of infected mixed lineage kinase domain-like (MLKL) and tumor necros

24 ion of the necroptotic effector pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) by the upstream

25 The pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) is an essential

26 with subsequent RIP3-dependent activation of mixed lineage kinase domain-like (MLKL) leading to necro

27 grammed form of necrosis, is executed by the mixed lineage kinase domain-like (MLKL) protein, which i

28 ontaining protein-3 (NLRP3) inflammasome and mixed lineage kinase domain-like (MLKL) protein-dependen

29 Total levels of RIP1, RIP3, and mixed lineage kinase domain-like (MLKL) proteins were in

30 tor-interacting protein kinase-3 (RIPK3) and mixed lineage kinase domain-like (MLKL) proteins.

31 interacting protein kinase 3 (RIPK3) and the mixed lineage kinase domain-like (MLKL) pseudokinase.

32 r RIP3 activation and phosphorylation of the mixed lineage kinase domain-like (MLKL) pseudokinase.

33 ylates and activates the downstream effector mixed lineage kinase domain-like (MLKL) to induce necrop

34 Mixed Lineage Kinase domain-Like (MLKL), a key player in

35 effector implicated in MSU crystal killing, mixed lineage kinase domain-like (MLKL), did not prevent

36 protein kinase 3 (RIPK3) and its substrate, mixed lineage kinase domain-like (MLKL).

37 nd its downstream effector, the pseudokinase mixed lineage kinase domain-like (MLKL).

38 e-3, eventually leading to the activation of mixed lineage kinase domain-like and plasma membrane per

39 Blocking necroptosis using mixed lineage kinase domain-like deficient mice or necro

40 HFD did not increase phosphorylated mixed lineage kinase domain-like in RIP3(-/-) mice.

41 kinase activity, but it remains dependent on mixed lineage kinase domain-like protein (MLKL) downstre

42 events in two forms of programmed necrosis [mixed lineage kinase domain-like protein (MLKL) in necro

43 is is not involved in APAP toxicity by using mixed lineage kinase domain-like protein (MLKL) knockout

44 her et al. demonstrate that the pseudokinase mixed lineage kinase domain-like protein (MLKL) particip

45 The expression level of mixed lineage kinase domain-like protein (MLKL), a key d

46 This approach revealed that mixed lineage kinase domain-like protein (MLKL), a key t

47 , we have demonstrated that the pseudokinase mixed lineage kinase domain-like protein (MLKL), which p

48 g virus infections, RIPK3 phosphorylates the mixed lineage kinase domain-like protein (MLKL), which t

49 nery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL).

50 eracting protein kinase 1 (RIPK1), RIPK3 and mixed lineage kinase domain-like protein (MLKL).

51 The mixed lineage kinase domain-like protein MLKL is a funct

52 RIP1 and RIP3 and their interaction with the mixed lineage kinase domain-like protein MLKL.

53 es receptor-interacting proteins 1 and 3 and mixed lineage kinase domain-like protein necroptotic sig

54 ing serine/threonine-protein kinase 3)-MLKL (mixed lineage kinase domain-like protein)-dependent prog

55 RIPK1 or RIPK3, but not the RIPK3 substrate mixed lineage kinase domain-like protein, attenuated TNF

56 ptosis, assessed by levels of phosphorylated mixed lineage kinase domain-like protein.

57 lving receptor-interacting protein 1 and the mixed lineage kinase domain-like protein.

58 ce and detect increased RIPK1 expression and mixed lineage kinase domain-like pseudokinase (MLKL) act

59 wn to require the formation of a RIPK1-RIPK3-mixed lineage kinase domain-like pseudokinase (MLKL) sig

60 3 (RIPK3)-mediated pathways of apoptosis and mixed lineage kinase domain-like pseudokinase (MLKL)-dep

61 either IFN-alpha/beta receptor signaling or mixed lineage kinase domain-like pseudokinase (MLKL)-dep

62 rylation and plasma membrane localization of mixed lineage kinase domain-like pseudokinase (MLKL).

63 eceptor-interacting protein kinase-1), MLKL (mixed lineage kinase domain-like pseudokinase) protein,

64 ous scaffolds that lead to the activation of mixed lineage kinase domain-like pseudokinase.

65 ivated, RIP3 kinase targets the pseudokinase mixed lineage kinase domain-like to drive cell lysis.

66 nase 1) and RIPK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like) associated in a multi-

67 croptosis, and the downstream effector MLKL (Mixed Lineage Kinase Domain-Like).

68 or of necroptosis, as well as phosphorylated mixed lineage kinase domain-like, an effector of necropt

69 Here we report the identification of mixed lineage kinase domain-like, MLKL, as a key RIP3 do

70 eficiency, cells develop sensitivity to RIP3-mixed lineage kinase domain-like-mediated necroptosis as

71 , which eventually lead to the activation of mixed lineage kinase domain-like.

72 In this paper, we show that the mixed lineage kinase dual leucine zipper kinase (DLK) se

73 ring Kinase (LZK/MAP3K13) is a member of the mixed lineage kinase family with high sequence identity

74 The mixed lineage kinase MLK3 plays a crucial role in compro

75 ceptor-interacting protein kinase-3 (RIPK3), mixed lineage kinase-like (MLKL) and NADPH oxidase.

76 The activation of mixed lineage kinase-like (MLKL) by receptor-interacting

77 eceptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway in eo

78 eptor-interacting protein kinase-3 (RIPK3)-a mixed lineage kinase-like (MLKL) signaling pathway in ne

79 g aberrant caspase-8-dependent apoptosis and mixed lineage kinase-like (MLKL)-dependent necroptosis.

80 ic cells also expose PS after phosphorylated mixed lineage kinase-like (pMLKL) translocation to the m

81 rotein kinase 1 (RIP1), RIP3, phosphorylated mixed lineage kinase-like protein (MLKL), phosphoglycera

82 e the endogenous dp5, its induction requires mixed-lineage kinase (MLK) and c-Jun N-terminal kinase (

83 The mixed-lineage kinase 3 (MLK-3) inhibitor URMC-099 provid

84 Mixed-lineage kinase 3 (MLK3) activates mitogen-activate

85 goal of this study was to determine whether mixed-lineage kinase 3 (MLK3) mediates the initial, ASK1

86 Here we demonstrate that mixed-lineage kinase 3 (MLK3), a MAP3K family member, ph

87 in-penetrant inhibitor with activity against mixed-lineage kinase 3 (MLK3), named URMC-099.

88 ts initiated by FGD1 that involves the MAP3K mixed-lineage kinase 3 (MLK3).

89 is study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of

90 r-interacting protein kinase (RIPK) 1/3- and mixed-lineage kinase domain-like (MLKL)-dependent necrop

91 ng protein kinase 3 (RIP3) and its substrate mixed-lineage kinase domain-like protein (MLKL) are core

92 The effector of necroptosis, phosphorylated mixed-lineage kinase domain-like protein (MLKL), was det

93 protein kinase-3 (RIPK3) phosphorylation of mixed-lineage kinase domain-like protein (MLKL), which r

94 kinases RIPK1/RIPK3 and the effector protein mixed-lineage kinase domain-like protein (MLKL).

95 teracting protein kinase-3 and its substrate mixed-lineage kinase domain-like protein play a crucial

96 Mixed-lineage kinase-3 (MLK3) is a mammalian mitogen-act

97 l death dependent on RIPK-1, RIPK-3, and the mixed-lineage kinase-like protein (MLKL).

98 CD40L induced activation of mixed-lineage-kinase-3 and JNK, leading to the subsequen

99 Here we demonstrate that the mixed lineage kinases (MLK1-4) are MEK kinases that reac

100 Mixed lineage kinases (MLKs) have been implicated in cyt

101 tivation of the MAPK-kinase-kinases (MAP3Ks) mixed lineage kinases (MLKs)-2 and -3.

102 One is CEP-1347, an inhibitor of mixed lineage kinases that elicits neuroprotective and a

103 Similar to the closely related mixed-lineage kinases, LRRK2 can undergo autophosphoryla

104 kinase domain based on sequence homology to mixed-lineage kinases.

105 The conserved Mixed Lineage Leukaemia (MLL) complex deposits activatin

106 This modification is catalyzed by the mixed lineage leukaemia (MLL) family of histone methyltr

107 The mixed lineage leukaemia (MLL) family of proteins (includ

108 ent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene initiate aggressive f

109 and MEIS1 have essential oncogenic roles in mixed lineage leukaemia (MLL)-rearranged leukaemia.

110 Menin also interacts with mixed lineage leukaemia protein 1 (MLL1), a histone H3 l

111 ted or myelodysplasia-related AML (n=12), or mixed-lineage leukaemia (n=14) were enrolled at eight ce

112 Here we show that the trxG member Mll1 (mixed-lineage leukaemia 1) is required for neurogenesis

113 216 patients with AML, excluding those with mixed-lineage leukaemia.

114 Mixed lineage leukemia (MLL) and its metazoan Trithorax

115 c-Myb, GATA-3, Menin, and mixed lineage leukemia (MLL) bound to CGRE in human prim

116 nic fusions of the Trithorax-related protein mixed lineage leukemia (MLL) can initiate aggressive leu

117 allosteric changes that transcription factor mixed lineage leukemia (MLL) causes to the interactions

118 Mixed lineage leukemia (MLL) family histone methyltransf

119 The oncoprotein Ash2L is a component of the mixed lineage leukemia (MLL) family members 1-4, Setd1A,

120 Although misregulation of mixed lineage leukemia (MLL) family proteins has been as

121 Mixed lineage leukemia (MLL) fusion genes arise from chr

122 ne 79 (K79) on histone H3 and is involved in Mixed Lineage Leukemia (MLL) fusion leukemogenesis; howe

123 unctions and in leukemogenesis driven by the mixed lineage leukemia (MLL) fusion oncogene MLL-AF9.

124 ough menin acts as an oncogenic cofactor for mixed lineage leukemia (MLL) fusion protein-mediated his

125 polymerase-associated factor complex (PAFc), mixed lineage leukemia (MLL) fusion proteins activate ge

126 unctions as a critical oncogenic cofactor of mixed lineage leukemia (MLL) fusion proteins in the deve

127 The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required

128 Mixed lineage leukemia (MLL) fusion-driven acute leukemi

129 Chromosomal translocations of the mixed lineage leukemia (MLL) gene are a common cause of

130 ith chromosomal translocations involving the mixed lineage leukemia (MLL) gene are usually associated

131 Chromosome translocations involving the mixed lineage leukemia (MLL) gene fuse it in frame with

132 first identified as a fusion partner of the mixed lineage leukemia (MLL) gene in acute myeloid leuke

133 The mixed lineage leukemia (MLL) gene is also frequently inv

134 Translocations of the mixed lineage leukemia (MLL) gene occur in 60% to 80% of

135 Chromosomal rearrangements of the mixed lineage leukemia (MLL) gene occur in ~10% of B-cel

136 The mixed lineage leukemia (MLL) gene plays a critical role

137 Chromosomal translocations involving the Mixed Lineage Leukemia (MLL) gene produce chimeric prote

138 of infants with ALL, particularly those with mixed lineage leukemia (MLL) gene rearrangements, is onl

139 Chromosomal translocations targeting the mixed lineage leukemia (MLL) gene result in MLL fusion p

140 to be a drug target for acute leukemia with mixed lineage leukemia (MLL) gene translocations.

141 kemia (B-ALL) harboring rearrangement of the mixed lineage leukemia (MLL) gene with CD19 CAR-T cells.

142 lso interacts with translocation partners of Mixed Lineage Leukemia (MLL) gene, which is commonly tra

143 receptors (ERs) and ER coregulators such as mixed lineage leukemia (MLL) histone methylases (MLL2 an

144 ights into the role of the Trithorax protein mixed lineage leukemia (MLL) in maintaining cancer stem

145 Mixed lineage leukemia (MLL) is a key epigenetic regulat

146 The histone methyltransferase Mixed Lineage Leukemia (MLL) is essential to maintain he

147 ome translocations, most often involving the mixed lineage leukemia (MLL) locus at 11q23.

148 plex (DotCom), which includes several of the mixed lineage leukemia (MLL) partners in leukemia such a

149 -protein interaction (PPI) between menin and mixed lineage leukemia (MLL) plays a critical role in ac

150 The mixed lineage leukemia (MLL) protein and its Drosophila

151 e Men1 gene product menin interacts with the mixed lineage leukemia (MLL) protein, a histone H3 lysin

152 Inhibition of the menin-mixed lineage leukemia (MLL) protein-protein interaction

153 WD repeat domain 5 (WDR5) and block the WDR5-mixed lineage leukemia (MLL) protein-protein interaction

154 ENL, and AF9, is recruited by HIV-1 Tat and mixed lineage leukemia (MLL) proteins to activate the ex

155 Aven stimulates the mRNA translation of the mixed lineage leukemia (MLL) proto-oncogene in an argini

156 The mixed lineage leukemia (MLL) proto-oncogene is a recurre

157 third plant homeodomain (PHD3) finger of the mixed lineage leukemia (MLL) proto-oncoprotein and a pol

158 Mixed lineage leukemia (MLL) represents a genetically di

159 sents the most common leukemogenic fusion of mixed lineage leukemia (MLL) to a cytoplasmic partner pr

160 regulator in the expression of HOX genes in mixed lineage leukemia (MLL)-based hematological maligna

161 d the miRNAs are aberrantly overexpressed in mixed lineage leukemia (MLL)-rearranged acute leukemias.

162 regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid le

163 hylation (H3K27me3/2) and inhibits growth of mixed lineage leukemia (MLL)-rearranged leukemia cells.

164 rates for pediatric patients suffering from mixed lineage leukemia (MLL)-rearranged leukemia remain

165 ranslocations, that approximately 43% of all mixed lineage leukemia (MLL)-rearranged leukemias are EV

166 the c-Myb/GATA-3 complex contained Menin and mixed lineage leukemia (MLL).

167 partner of both de novo and therapy-induced mixed lineage leukemia (MLL).

168 , we identify the histone-remodelling enzyme mixed lineage leukemia (MLL)3 as a clock-controlled fact

169 gulated in the pathophysiology of rearranged mixed lineage leukemia (MLL-r).

170 They demonstrate that the mixed lineage leukemia (MLL1) gene acts independently fr

171 Mixed Lineage Leukemia (MLL1) translocations encode fusi

172 F23, and NUP98-TOP1 physically interact with mixed lineage leukemia 1 (MLL1) and the non-specific let

173 Acute myeloid leukemia (AML) with mixed lineage leukemia 1 (MLL1) gene rearrangement is ch

174 Mixed lineage leukemia 1 (MLL1) is a histone H3 lysine 4

175 The epigenetic activator Mixed lineage leukemia 1 (MLL1) is paramount for embryon

176 rotein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays a critical role in

177 We show that the mixed lineage leukemia 1 (MLL1) protein, a histone methy

178 Menin is an essential oncogenic cofactor for mixed lineage leukemia 1 (MLL1)-mediated leukemogenesis

179 ulated by MOZ, mixed lineage leukemia 1, and mixed lineage leukemia 1 cofactor menin.

180 leukemia cell lines harboring the rearranged mixed lineage leukemia 1 gene.

181 of acute leukemias arise from fusion of the mixed lineage leukemia 1 protein (MLL) N terminus to a v

182 oregulators such as histone methylases MLL1 (mixed lineage leukemia 1) and MLL3 and CREB-binding prot

183 The MLL1 (mixed lineage leukemia 1) protein, which is often disrup

184 gnificant overlap in genes regulated by MOZ, mixed lineage leukemia 1, and mixed lineage leukemia 1 c

185 Lpt) is the N-terminal homolog of mammalian Mixed Lineage Leukemia 2 (MLL2/ALR), a core component of

186 transferases such as enhancer of zeste 2 and mixed lineage leukemia 2, histone demethylases including

187 ximately 50% reduction in gene dosage of the mixed lineage leukemia 3 (MLL3) gene, located on 7q36.1,

188 The MLL3 (mixed lineage leukemia 3) protein is a member of the hum

189 H3.3 is repressed by mixed lineage leukemia 5 (MLL5) in self-renewing GBM cel

190 Taspase1, the mixed lineage leukemia and TFIIAalpha-beta cleaving prot

191 ias that harbor translocations involving the mixed lineage leukemia gene (MLL) possess unique biologi

192 Mixed lineage leukemia gene (MLL) rearrangements (MLL-r)

193 Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in acute leukem

194 5 (WDR5) is a common component of mammalian mixed lineage leukemia methyltransferase family members

195 h an aberrant histone methyltransferase, the mixed lineage leukemia partial tandem duplication (MLL-P

196 ct the WD repeat-containing protein 5 (WDR5)-mixed lineage leukemia protein 1 (MLL1) complex across t

197 The mixed lineage leukemia protein MLL1 contains four highly

198 The mixed lineage leukemia protein-1 (MLL1) belongs to the S

199 Mixed lineage leukemia protein-1 (MLL1) is a member of t

200 The mixed lineage leukemia protein-1 (MLL1) is a member of t

201 DPY-30), a complex that is part of the MLL1 (mixed lineage leukemia protein-1) core complex but that

202 y, although PTIP and PA1 associate with MLL (mixed lineage leukemia) complexes and participate in tra

203 ves as a critical oncogenic cofactor of MLL (mixed lineage leukemia) fusion proteins in acute leukemi

204 e a drug target for acute leukemia with MLL (mixed lineage leukemia) gene translocations.

205 AMLs bearing MLL (mixed lineage leukemia) rearrangements are associated wi

206 The mixed lineage leukemia-1 (MLL1) core complex predominant

207 The mixed lineage leukemia-1 (MLL1) enzyme is a histone H3 l

208 Translocations and amplifications of the mixed lineage leukemia-1 (MLL1) gene are associated with

209 3 (IGF2BP3) is specifically overexpressed in mixed lineage leukemia-rearranged (MLL-rearranged) B-acu

210 nd its receptor (IL-17RB) in human and mouse mixed lineage leukemia-rearranged AML cells, which were

211 A notable exception is mixed lineage leukemia-rearranged infant ALL, where vene

212 ole and is a potential therapeutic target in mixed lineage leukemia.

213 sociated with infant acute lymphoblastic and mixed lineage leukemia.

214 impaired reconstitution of stem cell-derived mixed-lineage leukemia (MLL) AML, which represents an ag

215 isordered transcription factors, such as the mixed-lineage leukemia (MLL) and c-Myb peptides, at isol

216 more, we observed that SALL4 interacted with mixed-lineage leukemia (MLL) and co-occupied the HOXA9 p

217 t multiple MLL-fusion proteins implicated in mixed-lineage leukemia (MLL) associate with AFF4, ELLs,

218 g to a single surface of the KIX domain, the mixed-lineage leukemia (MLL) binding surface.

219 his targeting strategy does not affect other mixed-lineage leukemia (MLL) family histone methyltransf

220 A subgroup of leukemogenic mixed-lineage leukemia (MLL) fusion proteins (MFPs) incl

221 LEDGF associates with mixed-lineage leukemia (MLL) fusion proteins and menin a

222 Mixed-lineage leukemia (MLL) fusion proteins are potent

223 Mixed-lineage leukemia (MLL) fusions are potent oncogene

224 ary acute myelogenous leukemia involving the mixed-lineage leukemia (MLL) gene (11q23) translocations

225 hromosomal translocation that juxtaposes the mixed-lineage leukemia (MLL) gene and the AF4 gene.

226 OF REVIEW: Leukemia carrying mutation of the mixed-lineage leukemia (MLL) gene is particularly refrac

227 Chromosomal rearrangements involving the mixed-lineage leukemia (MLL) gene occur in primary and t

228 The mixed-lineage leukemia (MLL) gene often fuses with ENL a

229 Chromosomal translocations of the mixed-lineage leukemia (MLL) gene with various partner g

230 t B-ALL is chromosomal rearrangements of the mixed-lineage leukemia (MLL) gene.

231 The mixed-lineage leukemia (MLL) H3K4 methyltransferase prot

232 ost cell factor 1 (HCF1), a component of the mixed-lineage leukemia (MLL) histone methyltransferase c

233 It is fused to mixed-lineage leukemia (MLL) in leukemia, and missense m

234 Mixed-lineage leukemia (MLL) is a proto-oncogene frequen

235 t mutations such as FLT3 internal-tandem and mixed-lineage leukemia (MLL) partial-tandem duplications

236 Histone lysine methylation, mediated by mixed-lineage leukemia (MLL) proteins, is now known to b

237 determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by int

238 The t(4;11)(q21;q23) fuses mixed-lineage leukemia (MLL) to AF4, the most common MLL

239 gements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expre

240 Mixed-lineage leukemia (MLL), an epigenetic regulator, p

241 Mixed-lineage leukemia (MLL)-AF4 fusion arises prenatall

242 Myeloid/lymphoid or mixed-lineage leukemia (MLL)-family genes encode histone

243 t to chromatin as an effective treatment for mixed-lineage leukemia (MLL)-fusion leukemia' by Dawson

244 k the progression of certain cancers such as mixed-lineage leukemia (MLL)-rearranged leukemias.

245 In contrast, leukemia driven by mixed-lineage leukemia (MLL, encoded by KMT2A) fusions w

246 Mixed-lineage leukemia (MLL; also known as myeloid/lymph

247 down (KD) of a writer, the methyltransferase mixed-lineage leukemia 1 (Mll1) (n = 26), and an eraser,

248 tivators CREB-binding protein (CBP)/p300 and mixed-lineage leukemia 1 (MLL1) critically regulate circ

249 Chromosomal translocations of the Mixed-lineage leukemia 1 (MLL1) gene generate MLL chimer

250 Further, using a myeloid-specific mixed-lineage leukemia 1 (MLL1) knockout (Mll1(f/f)Lyz2(

251 Here, we show that mixed-lineage leukemia 1 (MLL1) protein is a key determi

252 Ash1l cooperated functionally with mixed-lineage leukemia 1 (Mll1), as combined loss of Ash

253 f the H3K4-specific methyltransferase, Kmt2a/Mixed-lineage leukemia 1 (Mll1), in mouse postnatal fore

254 expression of the histone methyltransferase, mixed-lineage leukemia 1 (MLL1), which specifically trim

255 onal identity in the murine brain requires a mixed-lineage leukemia 1 (Mll1)-dependent epigenetic mem

256 ultiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1).

257 istone-methyltransferase myeloid/lymphoid or mixed-lineage leukemia 2 (mll2/kmt2b) gene in adult fore

258 s identified were all of the subunits of the mixed-lineage leukemia 3 (Mll3) and 4 (Mll4) complexes,

259 The histone H3-lysine-4 methyltransferase mixed-lineage leukemia 3 (MLL3) and its closest homolog,

260 Although PTIP is a unique component of the mixed-lineage leukemia 3 (MLL3)/MLL4 chromatin-modifying

261 deficient in the PTIP component of the MLL3 (mixed-lineage leukemia 3)-MLL4 complex display impaired

262 umonji C family of proteins, associates with mixed-lineage leukemia 3/4 complexes.

263 Mixed-lineage leukemia 4 (MLL4/KMT2D) is a major enhance

264 Mixed-lineage leukemia 4 (MLL4; also called MLL2 and ALR

265 The human mixed-lineage leukemia 5 (MLL5) protein mediates hematop

266 ragile sites, and breakpoints, including the mixed-lineage leukemia breakpoint cluster region (MLL BC

267 Chromosome rearrangements involving the mixed-lineage leukemia gene (MLL) create MLL-fusion prot

268 adults as a result of rearrangements to the mixed-lineage leukemia gene (MLL) located on chromosome

269 atient-derived xenografts (PDX) of pediatric mixed-lineage leukemia gene (MLL)-rearranged ALL were es

270 MEN1 and its coactivator, the mixed-lineage leukemia histone methyltransferase, are re

271 ize the biology and optimal therapy of acute mixed-lineage leukemia in children, we reviewed the path

272 Here we demonstrate that the mixed-lineage leukemia protein (MLL) complex, a well-kno

273 its promoter, and p300, myeloid/lymphoid or mixed-lineage leukemia protein 4 (MLL4), and RNA polymer

274 ith the transcriptional activation domain of mixed-lineage leukemia protein leads to an enhancement o

275 The mixed-lineage leukemia protein MLL1 is a transcriptional

276 in leukemogenesis driven by a subset of MLL (mixed-lineage leukemia) fusion proteins raises the possi

277 to as MLL to denote the gene associated with mixed-lineage leukemia) generate MLL fusion proteins tha

278 horax family member MLL (myeloid/lymphoid or mixed-lineage leukemia) is presumed to activate Hox expr

279 The MLL (mixed-lineage leukemia) proto-oncogene encodes a histone

280 Mixed-lineage leukemia-1 (MLL1) has been shown to direct

281 The histone methyltransferase mixed-lineage leukemia-4 (MLL4) is a transcriptional coa

282 eptor NKp44 (NKp44L), a novel isoform of the mixed-lineage leukemia-5 protein, as a cellular ligand f

283 effectively treats aggressive AML, including mixed-lineage leukemia-driven AML, and outperforms stand

284 ing response to therapy, of 35 patients with mixed-lineage leukemia.

285 Mixed lineage leukemias (MLLs) are human histone H3 lysi

286 key roles of ERs in the recruitment of these mixed lineage leukemias into the HOXC6 promoter.

287 DM2 activates chk1 phosphorylation, elevates mixed lineage lymphoma histone methyl transferase levels

288 volved in T-cell signaling, and give rise to mixed-lineage lymphoma in vivo.

289 secreted signalling molecule Wnt1 generates mixed-lineage mammary tumours composed of basal and lumi

290 ts exhibited varied morphology, suggesting a mixed-lineage origin of tumor-initiating cells.

291 well as bipotential intermediates, manifest mixed-lineage patterns of gene expression at a single-ce

292 ete differentiation but often also display a mixed lineage phenotype.

293 Moreover, we uncovered a mixed-lineage population of cells that may reflect molec

294 tification of transcriptomes from individual mixed lineage progenitor cells in the chick as these cel

295 We report that disruption of the mixed-lineage protein kinase (MLK) - cJun NH2-terminal k

296 e Rac/Cdc42 interaction site (CRIB motif) on mixed-lineage protein kinases (MLKs).

297 We propose that mixed-lineage states are obligatory during cell-fate spe

298 Such mixed-lineage states may reflect the molecular priming o

299 The proposed method is a novel mixed lineage tree/sequence based method to detect withi

300 ting cells (TICs), which proliferate to form mixed-lineage tumors.